News and Events
Stem cell–derived natural killer cells engineered to attack solid tumors
Cancer-killing natural killer cells could pave the way to off-the-shelf immunotherapy for solid tumors.
Read More
Belzutifan works steadily in people with VHL-associated tumors
In a recent clinical trial, belzutifan shows long-lasting benefits for patients with von Hippel-Lindau disease.
Read More
Protein found on the common cold virus can activate anti-cancer immune response
Researchers found a viral protein that can activate certain immune cells to produce robust anti-cancer responses against liver cancer.
Read More
Clinical trial researching radiation for brain cancer
A clinical trial led by Peter Mathen, M.D., Staff Clinician in the Radiation Oncology Branch, is researching a safe schedule for using radiation for adults with glioblastoma.
Read More
New Milestones publication now available
Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This digital-only issue of our annual publication, Milestones, features 13 of our top scientific advances from the previous year. These discoveries fall everywhere on the spectrum from basic science to clinical research, ranging from a deeper understanding of the gut-liver axis and how bacteria move, to results and stories from three promising clinical trials. Our researchers have developed AI models to predict when tumors will respond to treatments, built scaffolds of biomaterials to assist with drug delivery, investigated how mitochondria function in healthy and diseased liver cells, and more.
Read More
Ruth Nussinov elected to the National Academy of Sciences
The National Academy of Sciences elected Ruth Nussinov, Ph.D., Senior Investigator in the Cancer Innovation Laboratory, as a member of their organization. She is being recognized for her groundbreaking achievements as a computational structural biologist.
Read More
Offering “life-sustaining” treatment without compromising quality of life
When Alison James received her diagnosis of squamous cell carcinoma, she was alarmed by the side effects associated with the standard of care. She traveled to the NIH Clinical Center for a CCR clinical trial that offered treatment with less impact to her quality of life.
Read More
Celebrating CCR Careers: Steven Z. Pavletic, M.D., Ph.D.
Steven Z. Pavletic, M.D., Ph.D., is a renowned expert in chronic graft-versus-host disease, a serious late complication that can happen after allogeneic bone marrow transplants. After serving at the NCI for over 20 years, he is now announcing his retirement.
Read More
T-cell receptors can help CAR T cells steer clear of healthy tissue while they attack tumors
Adding a specific T-cell receptor to CAR T cells may reduce side effects of immunotherapies designed to target solid tumors.
Read More
Study uncovers mechanism behind effectiveness of three-drug combination in patients with a rare bile duct cancer
Combining anti-VEGF therapy with immune checkpoint inhibitors stimulated the production of B cells to fight cholangiocarcinoma, a rare bile duct cancer.
Read More
Celebrating CCR Careers: Ira Pastan, M.D.
Ira Pastan, M.D., who pioneered receptor biology in animal cells and mentored several generations of scientists, announces his retirement from the NCI.
Read More